In conclusion, patients initiating DPP-4 inhibitors as third-line therapy in type 2 diabetes appeared to have lower discontinuation and have less hypoglycemia when compared to patients starting NPH insulin. Here, DPP4 is linked to type 2 diabetes mellitus.